TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6362017

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per kg body wt. 8 hourly for 7 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per kg body wt. 8 hourly for the first 4 days then 15 mg base per kg body wt. 8 hourly for the next 3 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per kg body wt. 8 hourly for 7 days and then sulfadoxine 30 mg per kg body wt. and pyrimethamine 1.5 mg per kg body wt.
Number of subjects: 77
Study: 29958706

Group type: EXPERIMENTAL
Intervention: Aged white wine (AWW)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gin
Number of subjects: 38
Study: 28362563

Group type: EXPERIMENTAL
Intervention: Cadila MMR vaccine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Serum MMR vaccine
Number of subjects: 328
Study: 27798034

Group type: EXPERIMENTAL
Intervention: Prophylactic tranexamic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prophylactic platelet transfusions
Number of subjects: 100
Study: 23815478

Group type: EXPERIMENTAL
Intervention: Conversational speech (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear speech (Experiment 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noise (Experiment 3a)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive load (Experiments 4a and 4b)
Number of subjects: 0
Study: 22081489

Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5‐3.5 mg/day) with or without prednisone
Number of subjects: 94
Study: 19176240

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting blood glucose concentrations of 2.8-4.4 mmol/L in infants and 3.9-5.6 mmol/L in children throughout PICU stay (n=349)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Conventional insulin therapy to prevent blood glucose from exceeding 11.9 mmol/L (n=351)
Number of subjects: 700
Study: 17209701

Group type: EXPERIMENTAL
Intervention: Induced negative mood
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Induced mood (general)
Number of subjects: 311
Study: 15934104

Group type: EXPERIMENTAL
Intervention: Persistent pain group (hip or knee pain at both baseline and follow-up)
Number of subjects: 3210

Group type: COMPARATOR
Intervention: Non-persistent pain group (hip or knee pain at baseline but no pain at follow-up)
Number of subjects: 3210
Study: 12741451

Group type: EXPERIMENTAL
Intervention: Coffee brewed with conduction roasting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control coffee (differently processed coffee)
Number of subjects: 30
Study: 8734235

Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone 1.5 mg.kg‐1 intravenously at the beginning of surgery and 1.5 mg.kg‐1 iv daily for three days after surgery)
Number of subjects: 32

Group type: COMPARATOR
Intervention: PANHD (preoperative acute normovolaemic haemodilution)
Number of subjects: 32
Study: 1827006

Group type: EXPERIMENTAL
Intervention: 1.25 mg isradipine twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2.5 mg isradipine twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg isradipine twice daily
Number of subjects: 45
Study: 7053912

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Propranolol combined with lactate and glycerol infusions
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 29946756

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU of cholecalciferol weekly for 24 weeks)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 28318098

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High BAT group (n = 6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low BAT group (n = 12)
Number of subjects: 18
Study: 24829053

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB) - 10 ml mepivacaine 1 % and 20 ml ropivacaine 0.375%
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anaesthesia (GA) - propofol, sunfentanil, desflurane
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anaesthesia + Interscalene brachial plexus block (GA + ISB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 120
Study: 22999817

Group type: EXPERIMENTAL
Intervention: Intensive Outpatient (IOP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Outpatient (OP)
Number of subjects: 300
Study: 21303402

Group type: COMPARATOR
Intervention: M‐MIST (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M‐MIST + EMD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M‐MIST + EMD + BMDX
Number of subjects: 45
Study: 19800722

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Moderate-protein diet (MPD)
Number of subjects: 423
Study: 16730604

Group type: EXPERIMENTAL
Intervention: Audio Computer-Assisted Self Interview (ACASI)
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Self-Administered (SA)
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Interviewer-Administered (IA)
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Paper-and-Pencil Self-Administered (SA)
Number of subjects: 2394
Study: 12738464

Group type: EXPERIMENTAL
Intervention: Infliximab 1 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 21
Study: 10874600

Group type: EXPERIMENTAL
Intervention: AAACa (900 mg/day elemental calcium)
Number of subjects: 4

Group type: COMPARATOR
Intervention: AACa (900 mg/day elemental calcium)
Number of subjects: 4

Group type: COMPARATOR
Intervention: CaCO3 (900 mg/day elemental calcium)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (no elemental calcium)
Number of subjects: 4
Study: 9059470

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm for 20 minutes
Number of subjects: 34

Group type: COMPARATOR
Intervention: Air (control) inhaled for 20 minutes
Number of subjects: 34
Study: 3490970

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 30
Study: 31301173

Group type: EXPERIMENTAL
Intervention: Conditional inference approach for obtaining confidence intervals for eQTL effect sizes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of GTEx Liver dataset (v6)
Number of subjects: 0
Study: 29568771

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (non-triclosan sutures)
Number of subjects: 102
Study: 25844507

Group type: EXPERIMENTAL
Intervention: Nonextraction (Class I malocclusion)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Nonextraction (Class II malocclusion)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Extraction (Class I malocclusion)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Extraction (Class II malocclusion)
Number of subjects: 103
Study: 24424780

Group type: EXPERIMENTAL
Intervention: Org 25935 (12 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22442168

Group type: EXPERIMENTAL
Intervention: Presence of silent infarcts (SIs)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Presence of microbleeds (MBs)
Number of subjects: 395

Group type: COMPARATOR
Intervention: No silent infarcts or microbleeds (control group)
Number of subjects: 395
Study: 20001536

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 90
Study: 18706998

Group type: EXPERIMENTAL
Intervention: Budesonide with ketoconazole (16mg) in jejunum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Budesonide with ketoconazole (16mg) in ileum
Number of subjects: 8

Group type: COMPARATOR
Intervention: Budesonide in colon
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenously administered budesonide
Number of subjects: 8
Study: 16887334

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 263

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 263
Study: 12791114

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 35
Study: 11039260

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 2,500 mg/day (1,000 mg of calcium)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Calcium acetate 1,000 mg (254 mg of calcium)
Number of subjects: 28
Study: 9001380

Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into orange juice
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into tomatoes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into lima beans
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: d2‐PteGlu6 blended into citrate buffer
Number of subjects: 7

Group type: COMPARATOR
Intervention: d2‐PteGlu6 blended into water (control)
Number of subjects: 7
Study: 1623349

Group type: EXPERIMENTAL
Intervention: Resurfacing
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Deep dermabrasion
Number of subjects: 3

Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 3
Study: 6394349

Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg b.d.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg + Triamterene 50 mg b.d.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Triamterene 50 mg b.d.
Number of subjects: 110
Study: 30053728

Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation for 28 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Post-exercise CAR‐ACR content after β‐alanine supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Supplementation alone
Number of subjects: 14
Study: 26459780

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sildenafil (100 mg)
Number of subjects: 64
Study: 23506257

Group type: EXPERIMENTAL
Intervention: Human breast milk
Number of subjects: 63

Group type: COMPARATOR
Intervention: Barrier cream (40% zinc oxide with cod liver oil formulation)
Number of subjects: 63
Study: 23776431

Group type: EXPERIMENTAL
Intervention: Low-vitamin B-6 diet (<0.5 mg/d)
Number of subjects: 23
Study: 20805344

Group type: EXPERIMENTAL
Intervention: Early class III protraction facemask treatment (PFG)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control/no treatment (CG)
Number of subjects: 73
Study: 18768335

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Combination of glucosamine and chondroitin sulfate
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1583
Study: 15940172

Group type: EXPERIMENTAL
Intervention: Entero-sorption with pectin-containing medication
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 150
Study: 12463728

Group type: EXPERIMENTAL
Intervention: Low-fat meal (two slices of bread and 200 ml of apple juice)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-fat meal (two slices of bread with 30 gm of butter and 200 ml of apple juice)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 9
Study: 10328649

Group type: EXPERIMENTAL
Intervention: Regenerative therapy using bioactive glass
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 15
Study: 7574019

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 81
Study: 1754868

Group type: EXPERIMENTAL
Intervention: IS-5-MN 20 mg b.i.d. or t.i.d.
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: s.r. nifedipine 20 mg b.i.d. or 40 mg b.i.d.
Number of subjects: 251

Group type: COMPARATOR
Intervention: IS-5-MN and s.r. nifedipine
Number of subjects: 251
Study: 7127996

Group type: EXPERIMENTAL
Intervention: Flecainide (200 to 300 mg b.i.d.)
Number of subjects: 9
Study: 31405823

Group type: EXPERIMENTAL
Intervention: Motivational physical activity program (G1)
Number of subjects: 123

Group type: COMPARATOR
Intervention: As usual care control group (G2)
Number of subjects: 123
Study: 31551206

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily for the first 21 days of each 28‐day cycle plus Best Supportive Care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m2 intravenously on Day 1 of each 21‐day cycle plus cisplatin 75 mg/m2 i.v. beginning 30 minutes after pemetrexed administration plus Best Supportive Care (BSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both regorafenib and pemetrexed
Number of subjects: 0
Study: 29149904

Group type: COMPARATOR
Intervention: 7-day standard triple therapy (lansoprazole, amoxicillin, and clarithromycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin, and metronidazole for another 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 0
Study: 26335108

Group type: EXPERIMENTAL
Intervention: Interactive videogame therapy (VGT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard therapy ROM activities (ST)
Number of subjects: 17
Study: 24744200

Group type: EXPERIMENTAL
Intervention: Dynamic 320-row multi-detector computed tomography (MDCT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Positron-emission tomography (PET)
Number of subjects: 32
Study: 22947344

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 19237874

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (insulin titrated to maintain blood glucose levels within the range of 4.44‐6.11 mM)
Number of subjects: 483
Study: 17389707

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) and isoprenaline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hormone-sensitive lipase gene expression
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gene expression of UCP2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gene expression of PDE3B
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gene expression of other genes
Number of subjects: 24
Study: 15466769

Group type: EXPERIMENTAL
Intervention: Multimethod quality improvement intervention
Number of subjects: 87291

Group type: COMPARATOR
Intervention: Less intensive intervention (Control)
Number of subjects: 87291
Study: 11812331

Group type: EXPERIMENTAL
Intervention: Ultrasound with Jieeryin as irrigant (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound with saline as irrigant (control group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand instruments (control group 1)
Number of subjects: 60
Study: 11097449

Group type: EXPERIMENTAL
Intervention: Bupivacaine alone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bupivacaine with betamethasone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 55
Study: 9075340

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) and Amodiaquine (AM)
Number of subjects: 0
Study: 8154130

Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal LDL precipitation (HELP)
Number of subjects: 0
Study: 3816921

Group type: EXPERIMENTAL
Intervention: Slow-release diltiazem (120 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional diltiazem tablet (120 mg)
Number of subjects: 12
Study: 30488789

Group type: EXPERIMENTAL
Intervention: Dalteparin (low-molecular-weight heparin)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (direct oral anticoagulant)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: General experience of anticoagulation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Awareness of thrombosis risk
Number of subjects: 37
Study: 28750840

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham-electroacupuncture (SA)
Number of subjects: 128
Study: 27200393

Group type: EXPERIMENTAL
Intervention: Z-plasty reconstruction
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional median neurolysis
Number of subjects: 52
Study: 24397361

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone capsules 200 mg once daily from the day after insemination until next menstruation or continuing for up to 8 weeks of pregnancy.
Number of subjects: 398

Group type: COMPARATOR
Intervention: No luteal phase support (control group).
Number of subjects: 398
Study: 22330964

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 759
Study: 20127893

Group type: EXPERIMENTAL
Intervention: Viewing acoustic cardiography
Number of subjects: 90

Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 90
Study: 18336723

Group type: EXPERIMENTAL
Intervention: Regular cleaning products containing hypochlorite
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Regular products plus three additional products with dilute hypochlorite
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no products)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Asthmatic product groups (hypochlorite-based cleaning supplies)
Number of subjects: 3
Study: 15372158

Group type: EXPERIMENTAL
Intervention: Facial electromyography (EMG) measuring joy-relevant facial muscles (zygomaticus major, orbicularis oculi, levator labii superioris)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Facial electromyography (EMG) measuring nonjoy-relevant facial muscles (frontalis, corrugator supercilii)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 40
Study: 12190757

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham pressure (Control)
Number of subjects: 50
Study: 9880379

Group type: COMPARATOR
Intervention: Vigorous exercise <1 time per week
Number of subjects: 21823

Group type: EXPERIMENTAL
Intervention: Vigorous exercise 1 time per week
Number of subjects: 21823

Group type: EXPERIMENTAL
Intervention: Vigorous exercise 2 to 4 times per week
Number of subjects: 21823

Group type: EXPERIMENTAL
Intervention: Vigorous exercise ≥5 times per week
Number of subjects: 21823

Group type: COMPARATOR
Intervention: Vigorous exercise <1 time per week (after additional adjustments)
Number of subjects: 21823

Group type: EXPERIMENTAL
Intervention: Vigorous exercise 1 time per week (after additional adjustments)
Number of subjects: 21823

Group type: EXPERIMENTAL
Intervention: Vigorous exercise 2 to 4 times per week (after additional adjustments)
Number of subjects: 21823

Group type: EXPERIMENTAL
Intervention: Vigorous exercise ≥5 times per week (after additional adjustments)
Number of subjects: 21823
Study: 7493433

Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 i.u. per day for 4 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1771216

Group type: EXPERIMENTAL
Intervention: 2 mg dexamethasone phosphate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone phosphate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31977634

Group type: EXPERIMENTAL
Intervention: Vaccination within 2 h after the last training session
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vaccination after 24‐26 h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Brisbane strain neutralization titers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 45
Study: 28855077

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab pooled
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study: 26159458

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dasatinib or Nilotinib
Number of subjects: 54
Study: 24334945

Group type: EXPERIMENTAL
Intervention: Coartem (artemether-lumefantrine)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Larimal (artesunate plus amodiaquine)
Number of subjects: 182
Study: 21092353

Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT combined with antidepressants
Number of subjects: 34

Group type: COMPARATOR
Intervention: Antidepressants alone (treatment as usual)
Number of subjects: 34
Study: 19329835

Group type: EXPERIMENTAL
Intervention: Non-calcium containing phosphate binder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcimimetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17667736

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15359542

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (1.0% hydrogen peroxide, 0.243% sodium fluoride, sodium tripolyphosphate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of Test Dentifrice to Control Dentifrice
Number of subjects: 44